IP Strategy for MedTech Startups: What Early-Stage Companies Often Miss

Why IP Strategy Should Start Early in MedTech Development

Many early-stage MedTech companies assume that intellectual property strategy becomes relevant only once the product is clearly defined.

However, during the webinar "From R&D to market: IP and regulatory strategy across the product life cycle", Anne-Sophie Grell challenged this assumption from a regulatory perspective. Product definition, regulatory classification, and development strategy all influence what can — and should — be protected through intellectual property.

In practice, IP strategy is most effective when it evolves alongside regulatory strategy and product development. When these elements are aligned early, companies can protect their innovation more effectively and avoid costly strategic adjustments later in development.

1. Patent Filing Decisions Often Come Too Late

One of the most common ways early-stage companies unintentionally weaken their intellectual property protection is through premature public disclosure.

Many routine activities in product development can count as public disclosure events, including:

• Conference presentations
• Investor discussions
• Scientific publications
• Clinical trial registrations

Once key product information becomes public, the novelty requirement for patent protection may be compromised.

For this reason, early coordination between regulatory, R&D, and IP teams is essential. When these teams collaborate early in development, patent filings can be planned and submitted before key disclosures occur.

This ensures that companies retain strong patent protection while continuing to communicate with investors, partners, and the scientific community.

2. Patent Landscapes Reveal Where Competitors Are Going

Another key insight from the webinar was the strategic value of patent landscape analysis.

Competitor patent filings often reveal technological directions long before new products reach the market. By analysing patent portfolios, companies can identify which technologies competitors are exploring and how product profiles may evolve over time.

In one example discussed during the webinar, competitor patents revealed that several companies were developing treatments with longer dosing intervals than the product currently under development.

This insight triggered an internal discussion about the product's competitive positioning. If competitors were moving toward longer treatment intervals, the company needed to reassess whether its own development strategy would remain competitive in the long term.

💡 Patent landscape analysis therefore serves not only as an IP monitoring tool but also as a strategic intelligence resource for product development and market positioning.

3. Medical Device IP Follows Different Rules Than Pharmaceuticals

Patent strategies for medical devices differ significantly from those used for pharmaceuticals.

In Europe, certain treatment methods cannot be claimed directly in patents. Instead, intellectual property protection must focus on the device, system, or technical mechanism that enables the treatment.

For example, patents may protect:

• The device architecture
• The delivery mechanism
• The technical system enabling the treatment
• The interaction between device components

Understanding these legal nuances is essential when developing a robust IP strategy for medical devices. Without careful claim design, patents may fail to provide meaningful protection against competitors.

For emerging MedTech companies, early collaboration with experienced IP counsel is therefore critical.

4. Align Your IP Strategy With Your Regulatory Pathway

Anne-Sophie also emphasised the importance of aligning patent claims with the regulatory description of the product.

Regulatory submissions require manufacturers to define the intended use of the device clearly. This intended use forms the foundation of regulatory classification, conformity assessment, and clinical evaluation.

If patent claims describe a mechanism or application that differs from the regulatory intended use, inconsistencies may arise between the patent portfolio and regulatory documentation.

Such inconsistencies can create complications during:

• Regulatory submissions
• Investor due diligence
• Licensing negotiations
• Partnership discussions

💡 Early coordination between regulatory experts and IP counsel helps ensure that patent strategy and regulatory strategy evolve together, strengthening both the patent portfolio and the development pathway.

The Bigger Picture: IP, Regulatory Strategy and Product Development

For emerging MedTech companies, intellectual property strategy should not be treated as a standalone legal activity.

Instead, it should evolve together with:

• Product development
• Regulatory classification
• Clinical strategy
• Competitive landscape analysis

Companies that integrate these elements early are better positioned to protect their innovation, attract investment, and navigate regulatory pathways successfully.

In other words, strong IP protection is not simply the result of filing patents. It is the result of strategic alignment between innovation, regulation, and market positioning.

Watch the Full Webinar on Demand

This article is based on the webinar:

"From R&D to market: IP and regulatory strategy across the product life cycle" by QbD Group, Gevers & Biovia

In this session, experts discuss how IP strategy, regulatory pathways, and product development interact throughout the lifecycle of innovative healthcare technologies.

Webinar on demand

🎬 Watch the full session on demand

Watch now

Navigate Regulatory Complexity with Confidence

Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.